A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
|Articles|October 15, 2004
Study shows advantages of holmium laser for BPH
Tauranga, New Zealand--By almost all parameters measured, the efficacy of holmium laser transurethral procedures in the prostate match or exceed that of similar open and transurethral procedures, according to a significant body of work by Peter J. Gilling, MD, urologic consultant at Tauranga Hospital, New Zealand. Dr. Gilling's research has centered on two procedures'holmium laser resection of the prostate (HoLRP) and holmium laser enucleation of the prostate (HoLEP)-although HoLRP has essentially been replaced by the 100-watt HoLEP (Lumenis, Santa Clara, CA).
Advertisement
Advertisement
Related to this article
The PDUFA target action date is in the fourth quarter of 2026.
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
The AACU and the WOCN Society urge CMS to protect access to individualized catheter and ostomy supplies as competitive bidding begins in 2028.
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves belzutifan plus lenvatinib for advanced clear cell renal cell carcinoma
2
FDA grants priority review to perioperative durvalumab plus enfortumab vedotin in MIBC
3
After curative-intent treatment, prostate cancer recurrence is still an unmet need
4
Sandip Prasad, MD, on patient selection for chemoablation in LG-IR-NMIBC
5